April 26th 2024
This initiative will provide a variety of tools to promote awareness and education, including some resources in both English and Spanish.
Ocugen, Inc. announces FDA clearance of IND amendment to Initiate OCU400 Phase 3 clinical trial
April 8th 2024According to the company, the Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.